Oramed Pharmaceuticals (ORMP) Operating Leases (2019 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Operating Leases came in at $493000.0 in Q1 2026, up 310.83% YoY from $120000.0 in Q1 2025, and down 8.7% on a QoQ basis from $540000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Operating Leases (2019 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 8 years of Operating Leases data on file, last reported at $493000.0 in Q1 2026.
- Quarterly Operating Leases rose 310.83% year-over-year to $493000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $493000.0 (up 310.83% YoY) and the FY2025 annual result came in at $540000.0, up 246.15% from the prior year.
- Operating Leases slipped to $493000.0 in Q1 2026, from $540000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $1.1 million in Q1 2022 to a low of $120000.0 in Q1 2025.
- A 5-year average of $482000.0 and a median of $493000.0 in 2026 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases slumped 55.88% — and 2026, when it surged 310.83%.
- Tracing ORMP's Operating Leases over 5 years: stood at $647000.0 in 2022, then sank by 47.14% to $342000.0 in 2023, then plunged by 54.39% to $156000.0 in 2024, then soared by 246.15% to $540000.0 in 2025, then retreated by 8.7% to $493000.0 in 2026.
- The last three Operating Leases figures came in at $493000.0 (Q1 2026), $540000.0 (Q4 2025), and $589000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 484,000.00 |
| Mar 31, 2026 | 493,000.00 |
| Dec 31, 2025 | 540,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | 648,000.00 |
| Mar 31, 2025 | 120,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 236,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 342,000.00 |
| Sep 30, 2023 | 389,000.00 |
| Jun 30, 2023 | 488,000.00 |
| Mar 31, 2023 | 564,000.00 |
| Dec 31, 2022 | 647,000.00 |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 744,000.00 |
| Mar 31, 2022 | 1.11 Mn |
| Nov 30, 2021 | 374,000.00 |
| Aug 31, 2021 | 533,000.00 |